MedTrace Logo

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

NCT00800007 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2009-02-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

ANZ-521

3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.

DRUG

Placebo

250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.

Sponsors & Collaborators

  • Anza Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800007 on ClinicalTrials.gov